Stock events for AngioDynamics, Inc. (ANGO)
Over the past six months, AngioDynamics' stock price has been impacted by several events. Strong fiscal Q1 2026 results in October 2025, with net sales up 12.2% year-over-year and the Med Tech segment growing by 26.1%, led to raised fiscal year 2026 revenue guidance. Fiscal Q2 2026 results in January 2026 showed continued double-digit Med Tech growth and increased profitability. The announcement in January 2026 that President and CEO Jim Clemmer intends to retire during fiscal year 2027 led to a 22% stock decline, reflecting investor concerns, but a formalized transition agreement with retention bonuses aims to ensure management stability. The stock's 52-week high was $13.99 and its 52-week low was $8.27. As of early March 2026, analysts have given AngioDynamics a consensus rating of "Moderate Buy" with an average one-year target price of $19.33.
Demand Seasonality affecting AngioDynamics, Inc.’s stock price
There is evidence of demand seasonality for AngioDynamics' products and services. The company has indicated that its first-quarter cash utilization is seasonally high due to incentive compensation and insurance expenses. Conversely, strong cash flow in the fourth quarter is anticipated, aided by higher sales and seasonal trends.
Overview of AngioDynamics, Inc.’s business
AngioDynamics, Inc. is a medical technology company specializing in minimally invasive medical devices, operating in the healthcare sector, specifically in the medical instruments and supplies industry. The company provides interventional medical technology for oncology, vascular surgery, and urology, with key products including the NanoKnife ablation system, AlphaVac mechanical thrombectomy system, BioFlo vascular access products, and the Auryon atherectomy platform. The Med Tech segment, including Auryon, the thrombus management platform, and NanoKnife, has been a significant driver of revenue growth.
ANGO’s Geographic footprint
AngioDynamics, Inc. has a global presence, operating in over 80 countries, primarily in the United States and Europe.
ANGO Corporate Image Assessment
AngioDynamics has maintained a positive brand reputation over the past year through its innovative product offerings and clinical achievements. The NanoKnife System was named to TIME's 2025 Best Inventions list for its use in ablating prostate tissue while preserving nearby structures, following a U.S. FDA 510(k) clearance in late 2024 and positive results from the PRESERVE study. The company has also achieved significant clinical milestones with the first patient enrollments in its AMBITION BTK and RECOVER-AV trials. Analyst sentiment is notably optimistic, with a "Moderate Buy" consensus rating from brokerages.
Ownership
AngioDynamics' ownership structure is a mix of institutional, retail, and individual investors. Institutional investors hold a significant majority of the company's stock, approximately 89.43% as of July 2025. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., Point72 Asset Management, L.P., and Systematic Financial Management Lp. Other notable institutional holders include Kotler Kevin, Armistice Capital, Llc, Weber Capital Management Llc /adv, Nuveen, LLC, State Street Corp, and Royce & Associates Lp.
